Septerna, Inc. - Common Stock (NQ:SEPN)

34.13 -0.62 (-1.77%)

Streaming Delayed Price Updated: 10:09 AM EDT, Jun 30, 2026 Add to My Watchlist

Price and Volume

Volume	33,813
Open	34.69
Bid (Size)	34.03 (300)
Ask (Size)	34.24 (100)
Prev. Close	34.75
Today's Range	33.36 - 34.69
52wk Range	10.30 - 37.99
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? ↗

June 29, 2026

This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.

Via The Motley Fool

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

June 08, 2026

From Septerna, Inc.

Via Business Wire

Performance

YTD	+22.0%	+22.0%
1 Month	+13.9%	+13.9%
3 Month	+46.5%	+46.5%
6 Month	+20.3%	+20.3%
1 Year	+222.9%	+222.9%

More News

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

May 11, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna to Present at Bank of America Securities Health Care Conference

May 05, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

April 13, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

March 09, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

March 01, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

February 10, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

January 08, 2026

From Septerna, Inc.

Via GlobeNewswire

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna to Participate in 8th Annual Evercore Healthcare Conference

November 25, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

November 10, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna to Participate in Upcoming Investor Conferences

November 03, 2025

From Septerna, Inc.

Via GlobeNewswire

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗

October 15, 2025

Via MarketBeat

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

September 29, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna to Participate in Upcoming Investor Conferences

August 27, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

August 21, 2025

From Septerna, Inc.

Via GlobeNewswire

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

August 11, 2025

From Septerna, Inc.

Via GlobeNewswire

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗

June 23, 2025

Via Benzinga

This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

June 23, 2025

Via Benzinga

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 23, 2025

Via Benzinga

The Analyst Verdict: Septerna In The Eyes Of 4 Experts ↗

June 23, 2025

Via Benzinga

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly ↗

May 29, 2025

Via Investor's Business Daily

Frequently Asked Questions

Is Septerna, Inc. - Common Stock publicly traded?

Yes, Septerna, Inc. - Common Stock is publicly traded.

What exchange does Septerna, Inc. - Common Stock trade on?

Septerna, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Septerna, Inc. - Common Stock?

The ticker symbol for Septerna, Inc. - Common Stock is SEPN on the Nasdaq Stock Market

What is the current price of Septerna, Inc. - Common Stock?

The current price of Septerna, Inc. - Common Stock is 34.13

When was Septerna, Inc. - Common Stock last traded?

The last trade of Septerna, Inc. - Common Stock was at 06/30/26 10:09 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.